Clinical Trial

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-30; most recent amendment 2025-11-26.
Status change: Not Yet Recruiting → Recruiting 2023-12-08
Trial Details
NCT Number NCT05979051
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Eosinophilic Granulomatosis With Polyangiitis
Enrollment 166 participants
Start Date 2023-11-16
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-04